Loading
NYSEHealthcareMedical - Diagnostics & Research
Latest quote
$44.53
−$0.26 · -0.58%
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Latest quote
$44.53
−$0.26 · -0.58%
After-hours
$44.53
$0.00 · 0.00%
Oct 8, 4:09 PM ET
Regular session · ET · Market data may be delayed.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Day range
Current $44.53
52-week range
Current $44.53
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
94
Deep Value
Sentiment
63
Bullish
Risk
41
Elevated Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Day range
Current $44.53
52-week range
Current $44.53
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell Mid-Cap ETFIWR37.89M0.07%55.97B USD0.18%$108.87+0.37%
iShares Russell 1000 Value ETFIWD20.51M0.03%81.91B USD0.18%$252+0.49%
First Trust Health Care AlphaDEX FundFXH15.5M1.38%1.12B USD0.61%$128.39-0.32%
iShares Russell Mid-Cap Value ETFIWS13.84M0.09%15.06B USD0.23%$163.89+0.68%
Invesco Biotechnology & Genome ETFPBE12.01M2.91%412.43M USD0.59%$94.065-0.80%
iShares Systematic Alternatives Active ETFIALT6.37M0.09%7.4B USD0.99%$29.91-0.37%
iShares Russell 1000 ETFIWB6.36M0.01%49.53B USD0.15%$422.52-0.39%
iShares U.S. Healthcare ETFIYH5.83M0.15%4.01B USD0.37%$70.92-0.53%iShares Russell Mid-Cap ETFIWRiShares Russell 1000 Value ETFIWDFirst Trust Health Care AlphaDEX FundFXHiShares Russell Mid-Cap Value ETFIWSInvesco Biotechnology & Genome ETFPBEiShares Systematic Alternatives Active ETFIALTiShares Russell 1000 ETFIWBiShares U.S. Healthcare ETFIYHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
